Experience

Davis Polk advised the joint book-running managers and representatives of the several underwriters and the lead manager in connection with a $50 million public offering of common…

Davis Polk advised the representatives of the several initial purchasers, in connection with the offering by National Life Insurance Company of $350 million of its 5.250% fixed-to-floating…

Davis Polk advised Sumitomo Mitsui Financial Group, Inc. on its SEC-registered takedown offering of senior TLAC notes, which consisted of $750 million aggregate principal amount of 3.748%…

Davis Polk represented NPB Neue Privat Bank AG (“NPB”) in connection with the only non-prosecution agreement for a Category 1 Swiss Bank under the U.S. Department of Justice’s (“DOJ”) Swiss…

Davis Polk advised the joint lead managers in connection with Mizuho Financial Group, Inc.’s debut SEC-registered takedown offering of Australian dollar-denominated senior notes, which…

Davis Polk represented NPB Neue Privat Bank AG (“NPB”) in connection with the only non-prosecution agreement for a Category 1 Swiss Bank under the U.S. Department of Justice’s (“DOJ”) Swiss…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.6 billion aggregate principal amount of its 3.500% senior notes due 2023 and (ii) $400 million…

Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed on the NASDAQ Global Market under the symbol “EARS.” Auris…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ…

Davis Polk is advising affiliates of Goldman Sachs in connection with their acquisition of Boyd Corporation from affiliates of Genstar Capital. Financial terms of the transaction were not…